(NASDAQ: EYEN) Eyenovia's forecast annual revenue growth rate of 1,927.45% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Eyenovia's revenue in 2024 is $3,787.On average, 3 Wall Street analysts forecast EYEN's revenue for 2024 to be $217,171,637, with the lowest EYEN revenue forecast at $104,249,968, and the highest EYEN revenue forecast at $390,937,379. On average, 3 Wall Street analysts forecast EYEN's revenue for 2025 to be $578,824,253, with the lowest EYEN revenue forecast at $498,362,232, and the highest EYEN revenue forecast at $651,562,299.
In 2026, EYEN is forecast to generate $1,662,076,191 in revenue, with the lowest revenue forecast at $1,108,840,567 and the highest revenue forecast at $2,215,311,816.